Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP4 | P49662 | 1/20 | 0.31 |
| ▸ | CASP5 | P51878 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20632972 | 0.82 | KMT2A (0.35) | HPGDSATRCASP1CASP4CASP5 | |
| SCHEMBL16238209 | 0.81 | HPGDS (0.37) | HPGDSCASP1CASP4CASP5KHK | |
| SCHEMBL19670178 | 0.78 | CASP1 (0.40) | CASP1CASP4CASP5 | |
| SCHEMBL19670180 | 0.72 | HRH3 (0.34) | HPGDSATRCASP1CASP4CASP5 | |
| SCHEMBL19865041 | 0.70 | MAP4K4 (0.45) | ATRDRD2 | |
| SCHEMBL19365307 | 0.67 | ALOX5 (0.33) | — | |
| SCHEMBL19865061 | 0.65 | HTR3A (0.41) | — | |
| SCHEMBL19365510 | 0.63 | CHRNA3 (0.34) | — | |
| SCHEMBL27559338 | 0.61 | HRH3 (0.67) | — | |
| SCHEMBL25041785 | 0.61 | HPGDS (0.39) | HPGDSCASP1CASP4CASP5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HPGDS 1307/4885ATR 1768/4885CASP1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.